Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AtriCureATRC +2.82%79 Forward PE Ratio is 319.45 as of Jul. 30, 2026. GuruFocus rates ATRC with a GF Score™ of 79/100 and a GF Value™ of $39.31 (Fairly Valued). The stock has 3 warning signs investors should review. Among 390 Medical Devices & Instruments companies, AtriCure ranks worse than 97.18% on this metric.
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
AtriCure Forward PE Ratio Related Terms
AtriCure Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for AtriCure's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AtriCure Forward PE Ratio Chart
AtriCure Annual Data
Trend
Forward PE Ratio
AtriCure Quarterly Data
2026-03
2026-06
Forward PE Ratio
437.58
529.47
ATRC vs BLFS, PLSE, LMAT: Forward PE Ratio Comparison
For the Medical Instruments & Supplies subindustry, AtriCure's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AtriCure Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AtriCure's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where AtriCure's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
AtriCure (ATRC) has a Forward PE Ratio of 319.45 as of Jul. 30, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on AtriCure and its competitors. According to the industry distribution chart, AtriCure ranks #379 out of 390 companies in the Medical Devices & Instruments industry, placing it in the top 97.2%.
Is AtriCure's Forward PE Ratio too high?
AtriCure's current Forward PE Ratio is 319.45. The Medical Devices & Instruments industry median Forward PE Ratio is 19.24. AtriCure's value of 319.45 is 1560.8% above this industry median. Based on the distribution chart, AtriCure ranks #379 out of 390 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, AtriCure has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AtriCure's Forward PE Ratio compare to BLFS and PLSE?
According to the Medical Devices & Instruments industry distribution chart, AtriCure ranks #379 out of 390 companies for Forward PE Ratio. This places AtriCure in the lower half of its industry. The industry median Forward PE Ratio is 19.24. AtriCure's value of 319.45 is 1560.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 19.24, based on 390 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AtriCure's current Forward PE Ratio of 319.45 is 1560.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on AtriCure and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 19.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AtriCure's current Forward PE Ratio is 319.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AtriCure stock overvalued right now?
Based on GuruFocus' analysis, AtriCure (ATRC) is currently considered Fairly Valued. The stock's GF Value™ is $39.31, compared to a current price of $40.89 — trading 4% above its estimated fair value. The current Forward PE Ratio is 319.45 and 1560.8% above the Medical Devices & Instruments industry median of 19.24. AtriCure's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For AtriCure (ATRC), the current Forward PE Ratio is 319.45 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AtriCure (ATRC) Overvalued in 2026?
Based on GuruFocus' analysis, AtriCure stock appears to be overvalued.
The current stock price of $40.89 is trading 4% above its estimated GF Value™ of $39.31.
GuruFocus considers AtriCure to be Fairly Valued.
Key valuation signals for ATRC:
Forward PE Ratio: 319.45
GF Value™: $39.31 vs. price of $40.89 (4% above fair value)
Industry Position: 1560.8% above the Medical Devices & Instruments median (#379 of 390)
No single metric tells the full story. See the ATRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
79GF Score
Get the complete analysis for ATRC
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATRC has been successfully added to your 
